Yu Christopher, Pathan Faraz, Tan Timothy C, Negishi Kazuaki
Nepean Clinical School, University of Sydney, University of Sydney, Sydney, NSW, Australia.
Cardiology Department, Nepean Hospital, Sydney, NSW, Australia.
Front Cardiovasc Med. 2021 Sep 3;8:728215. doi: 10.3389/fcvm.2021.728215. eCollection 2021.
Cardio-oncology encompasses the risk stratification, prognostication, identification and management of cancer therapeutics related cardiac dysfunction (CTRCD). Cardiovascular imaging (CVI) plays a significant role in each of these scenarios and has broadened from predominantly quantifying left ventricular function (specifically ejection fraction) to the identification of earlier bio-signatures of CTRCD. Recent data also demonstrate the impact of chemotherapy on the right ventricle, left atrium and pericardium and highlight a possible role for CVI in the identification of CTRCD through tissue characterization and assessment of these cardiac chambers. This review aims to provide a contemporary perspective on the role of multi-modal advanced cardiac imaging in cardio-oncology.
心脏肿瘤学涵盖癌症治疗相关心脏功能障碍（CTRCD）的风险分层、预后评估、识别及管理。心血管成像（CVI）在上述每种情况中都发挥着重要作用，并且已从主要用于量化左心室功能（特别是射血分数）扩展到识别CTRCD的早期生物标志物。近期数据还表明化疗对右心室、左心房和心包有影响，并突出了CVI通过组织特征分析和对这些心腔的评估在识别CTRCD方面可能发挥的作用。本综述旨在提供关于多模态先进心脏成像在心脏肿瘤学中作用的当代观点。
